Zacks Investment Research
04 Mar 2026, 18:01 UTC · 29w ago
Verdict
Source says Upgrade to Strong Buy. We score CPRX +1.00 across two claims.
Score confirms the headline.
Upgrade to Strong Buy
Rating stated in the headline
+1.00strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Catalyst Pharmaceutical (CPRX) has been upgraded to a Zacks Rank #1 (Strong Buy).
So whatA top-tier analyst rating based on upward earnings estimate revisions typically triggers positive near-term price momentum.
More positive than 93% of claims this week
The upgrade for Catalyst Pharmaceutical is driven by an upward trend in consensus earnings estimates.
So whatImproving fundamental earnings expectations are a primary driver for institutional buying and valuation increases.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company was upgraded to a Zacks Rank #1 (Strong Buy) based on an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
3h ago
+31.6%
Price agrees with the score
$31.49 vs $23.92 close before publication (Mar 3) · not market-adjusted
CPRX chart →
